Michigan Business Tribune
SEE OTHER BRANDS

Your best source on business and economy news from Michigan

Michigan Business Tribune: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Michigan Business Tribune.

Press releases published on June 16, 2025

Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway

Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway

- New data show clinical safety and early efficacy of SANA, a first-in-class compound that targets creatine-dependent thermogenesis MONTEVIDEO, Uruguay, June 16, 2025 (GLOBE NEWSWIRE) -- Eolo Pharma, a clinical-stage biotechnology company developing …

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that …

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— RESEARCH TRIANGLE PARK, N.C., June 16, …

Giyani Receives Letter of Interest from EXIM for US$225 million

Giyani Receives Letter of Interest from EXIM for US$225 million

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Giyani Metals Corp. (TSXV:EMM, GR:A2DUU8) ("Giyani" or the "Company"), developer of the K.Hill Battery-Grade Manganese Project in Botswana ("K.Hill" or “the Project”), is pleased to announce that it received a non …

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit …

Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs

Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Guardian Capital LP (the “Manager”) announces the following regular cash distributions for the period ending June 30, 2025, in respect of the ETF series of the Guardian Capital funds listed below (the “Guardian …

Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device

Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19 …

Mavenir Signs Debt Recapitalization Transaction to Drive Continued Growth

Mavenir Signs Debt Recapitalization Transaction to Drive Continued Growth

Transaction to strengthen Mavenir’s balance sheet and support its strategic focus on its profitable Mobile Core segment Mavenir to refocus Open RAN investments on 4G and 5G software, will accelerate investment in AI Siris to be controlling shareholder with …

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful …

Coda Octopus Group Reports Fiscal Second Quarter 2025 Financial Results

Coda Octopus Group Reports Fiscal Second Quarter 2025 Financial Results

ORLANDO, FL, June 16, 2025 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA) a global market leader in real-time 4D/5D/6D imaging sonar technology for real-time subsea intelligence and cutting-edge diving technology, …

Chicago Atlantic Real Estate Finance Declares Common Stock Dividend of $0.47 for the Second Quarter of 2025

Chicago Atlantic Real Estate Finance Declares Common Stock Dividend of $0.47 for the Second Quarter of 2025

CHICAGO, June 16, 2025 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI), a commercial mortgage real estate investment trust, announced that its board of directors has declared a regular quarterly cash dividend of $0.47 per …

Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream

Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream

MIAMI, June 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 83rd Emerging Growth Conference on June 17 …

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia: FDA PDUFA goal date of August 15, 2025 TNX-102 SL demonstrated statistically significant improvement in the primary …

Anfield Files Notice of Intent to Conduct Drill Program As It Expands Its Hub-And-Spoke Uranium and Vanadium Production Model

Anfield Files Notice of Intent to Conduct Drill Program As It Expands Its Hub-And-Spoke Uranium and Vanadium Production Model

VANCOUVER, British Columbia, June 16, 2025 (GLOBE NEWSWIRE) -- Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to announce that it has filed a Notice of Intent (“NOI”), through its wholly owned …

USA Rare Earth and Moog Sign Memorandum of Understanding for Delivery of U.S.-Made Neo Magnets for Data Center Cooling Solutions

USA Rare Earth and Moog Sign Memorandum of Understanding for Delivery of U.S.-Made Neo Magnets for Data Center Cooling Solutions

STILLWATER, Okla., June 16, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company) today announced it has signed a memorandum of understanding (MOU) with Moog Electric Motion Solutions (Moog) for delivery of the Company’s neo …

Portillo’s Adds Veteran Restaurant Leader Gene Lee to Board of Directors

Portillo’s Adds Veteran Restaurant Leader Gene Lee to Board of Directors

CHICAGO, June 16, 2025 (GLOBE NEWSWIRE) -- Portillo’s (NASDAQ: PTLO), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today announced the appointment of Eugene I. Lee, Jr., a respected veteran of the restaurant industry …

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body …

Abcourt recoupe 4,1 g/t d’or sur 11 mètres en rainure sur l’ancien décapage de Cambior, prolonge la zone minéralisée sur maintenant 300m de long dans le secteur Cartwright du projet Flordin et présente une mise à jour corporative

Abcourt recoupe 4,1 g/t d’or sur 11 mètres en rainure sur l’ancien décapage de Cambior, prolonge la zone minéralisée sur maintenant 300m de long dans le secteur Cartwright du projet Flordin et présente une mise à jour corporative

ROUYN-NORANDA, Québec, 16 juin 2025 (GLOBE NEWSWIRE) -- Mines Abcourt Inc. (« Abcourt » ou la « Société ») (TSX Venture : ABI) (OTCQB : ABMBF) est heureuse d’annoncer ses plus récents résultats d’échantillonnage en rainure sur l’ancien décapage de Cambior …

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical …

Mirasol Signs MOU for the Sale of the Virginia Silver Project and Landholdings in Argentina for US$8 Million Plus 2% NSR Royalty

Mirasol Signs MOU for the Sale of the Virginia Silver Project and Landholdings in Argentina for US$8 Million Plus 2% NSR Royalty

Ampere Metals to acquire Virginia Project for a total consideration of US$ 8.0 million: US$5 million for the sale of the mineral rights and US$3 million for the sale of the landholdings over 5 years of scheduled payments Mirasol will retain a 2% NSR …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service